Jamjoom Pharmaceuticals Factory

Rising MENA Demand And Vision 2030 Investments Will Redefine Markets

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

19 Jul 25

AnalystConsensusTarget's Fair Value

ر.س178.41

12.2% undervalued

04 Sep

ر.س156.60

-10.1%

2.0%

-10.1%

2.0%

You can edit this narrative until Jul 19 8:08 PM. Then, changes will post as Updates.

Author's Valuation

ر.س178.4112.2% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates0

AnalystConsensusTarget Fair Value

ر.س178.41

12.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

10.84%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

18.98%

Calculation

ر.س633.87m

Earnings '28

33.18x

PE Ratio '28

ر.س21.03b

Market Cap '28

ر.س21.03b

Market Cap '28

70.00m

No. shares '28

ر.س300.49

Share Price '28

ر.س300.49 Share Price '28

Discounted to 2025 @ 18.98% p.a.

ر.س178.41

Fair Value '25